<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94119">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01947855</url>
  </required_header>
  <id_info>
    <org_study_id>1245.35</org_study_id>
    <nct_id>NCT01947855</nct_id>
  </id_info>
  <brief_title>Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel Group, 4-week Study to Evaluate the Efficacy of Empagliflozin (10 mg and 25 mg Administered Orally Once Daily) in Postprandial Glucose and 24-hour Glucose Variability in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of empagliflozin administered orally once daily in postprandial
      glucose and 24-hour glycaemic variability compared to placebo given for 4 weeks as
      mono-therapy in Japanese patients with type 2 diabetes mellitus with insufficient glycaemic
      control on no antidiabetic treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in area under the concentration-time curve (AUC1-4h) for postprandial plasma glucose from baseline after 28 days of treatment</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Empagliflozin low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin low dose tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin high dose tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet matching Empagliflozin low dose</description>
    <arm_group_label>Empagliflozin high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin low dose</description>
    <arm_group_label>Empagliflozin low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet matching Empagliflozin high dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet matching Empagliflozin low dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin high dose tablet once daily</description>
    <arm_group_label>Empagliflozin high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet matching Empagliflozin high dose</description>
    <arm_group_label>Empagliflozin low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of type 2 diabetes mellitus prior to informed consent

          -  Male and female patients on diet and exercise regimen for 12 weeks prior to informed
             consent who are:

               -  drug-na√Øve, defined as no antidiabetic drugs for at least 12 weeks prior to
                  informed consent or,

               -  pre-treated with one oral antidiabetic drug (except sulfonylurea and
                  thiazolidinedione); the present antidiabetic therapy has to be unchanged for at
                  least 12 weeks prior to the informed consent. (Sulfonylurea is permitted as
                  pre-treatment drug only if the dose is equal or less than a half of daily
                  maximum approval dose.)

          -  Glycosylated haemoglobin (HbA1c) at Visit 1 (screening)

               -  for patients without antidiabetic therapy : HbA1c &gt;=7.0 to =&lt;10.0%

               -  for patients with one oral antidiabetic drug : HbA1c &gt;=7.0 to =&lt;9.5%

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level &gt;240 mg/dL (&gt;13.3 mmol/L)

          -  Impaired renal function, defined as estimated glomerular filtration rate (eGFR) &lt;60
             mL/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal
             disease (MDRD) formula)

          -  Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks
             prior to informed consent

          -  Indication of liver disease, defined by serum levels of either alanine transaminase
             (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper
             limit of normal (ULN)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.35.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjyuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.35.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita-shi, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>September 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
